Immunology (Vectors)

Transient Immunosuppression Allows Readministration of AAV Vectors

Published in Gene Therapy Weekly, April 6th, 1998

The transient use of immunosuppressive antibodies at the time of first adeno-associated viral (AAV) vector administration allows successful readministration of the same vector at a later date.

AAV vectors are very useful vehicles for gene transfer. Like other viral vectors, however, initial transgene expression diminishes over time and readministration of the vector is limited because of the host's initial immune response to viral components of the vector.

William C. Manning and colleagues from Chiron Corporation, California, demonstrated that the use of immunosuppressive antibodies during initial vector administration would allow transgene...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry